Search

Repligen Corp

Closed

SectorHealthcare

163.81 2.76

Overview

Share price change

24h

Current

Min

162.34

Max

164.28

Key metrics

By Trading Economics

Income

-3.3M

5M

Sales

9.9M

204M

P/E

Sector Avg

201.452

68.51

EPS

0.54

Profit margin

2.453

Employees

2,000

EBITDA

-35M

-2.4M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+5.22% upside

Dividends

By Acuity

Next Earnings

27 Oct 2026

Market Stats

By TradingEconomics

Market Cap

907M

8.3B

Previous open

161.05

Previous close

163.81

Repligen Corp Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2026, 22:01 UTC

Repligen Corp shares are higher in after-market trading, continuing a trend of six consecutive sessions. Broader equity gains follow weaker employment data easing rate hike concerns.

6 Aug 2026, 20:02 UTC

Repligen Corp shares are higher today, continuing gains from Wednesday. No specific company news was identified to explain the movement.

5 Aug 2026, 20:02 UTC

Correlated Moves

Repligen Corp shares are higher today, bolstered by gains in Charles River Laboratories and positive sentiment in the life sciences sector.

4 Aug 2026, 19:56 UTC

Repligen Corp shares are higher today, reflecting broader market strength amid a significant decline in crude oil prices. The stock is near its one-month range's upper end.

31 Jul 2026, 20:02 UTC

Repligen Corp shares are lower today amid broader market pressures and rising US Treasury yields. The stock reached a session low earlier.

30 Jul 2026, 21:02 UTC

Repligen Corp shares are higher in after-market trading, buoyed by positive investor sentiment amid a focus on corporate earnings and broader market trends.

29 Jul 2026, 16:12 UTC

Repligen Corp shares are lower Wednesday, breaking a trend of higher daily closes. Broader market conditions reflect rising crude oil prices and inflation concerns.

28 Jul 2026, 23:21 UTC

Repligen Corp shares are higher in after-market trading, reflecting strong momentum and trading near the upper end of its one-month range.

27 Jul 2026, 16:26 UTC

News

Repligen Corporation shares are lower as the company approaches its Q2 earnings report, with analysts projecting 10.7% revenue growth. Current price is $131.96.

24 Jul 2026, 19:06 UTC

News

Repligen Corp is under scrutiny as a stock to avoid, with concerns over its $763.3 million revenue and declining operating margins. Shares are trading lower today.

22 Jul 2026, 19:25 UTC

News
Event
Social Media

Repligen Corp is acquiring BioLife Solutions for about $1.5 billion, offering $11.25 in cash and stock, with a projected $20 million in synergies.

21 Jul 2026, 22:56 UTC

Repligen Corp shares are higher in after-market trading, despite a recent trend of lower closes. Broader market sentiment may be influenced by the Nikkei 225 surge.

20 Jul 2026, 18:06 UTC

Repligen Corp shares are higher today, reflecting positive market sentiment despite earlier intraday fluctuations. No specific news was identified to explain the movement.

Peer Comparison

Price change

Repligen Corp Forecast

Price Target

By TipRanks

5.22% upside

12 Months Forecast

Average 172.45 USD  5.22%

High 207 USD

Low 145 USD

Based on 13 Wall Street analysts offering 12 month price targets forRepligen Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

12

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat